真实世界2年前瞻性研究:类风湿关节炎药物减量队列(RHEUMTAP)中病情控制良好患者的减药结局
RHEUMTAP前瞻性队列纳入131例病情持续缓解或低疾病活动度的类风湿关节炎患者,其中52例接受减药或停药,随访2年。任何减药/停药者发生复发的风险为未减药者的10倍(HR 10.43,95%CI 2.98-36.53,P=0.0002);仅减csDMARD组复发风险较减bDMARD/tsDMARD组低91%(HR 0.09,95%CI 0.01-0.69,P=0.0213)。
要点
- 任何减药/停药者复发风险为未减药者的10倍(HR 10.43,95%CI 2.98-36.53,P=0.0002)。
- 减bDMARD/tsDMARD组复发风险为未减药组的31倍(HR 31.43,95%CI 6.35-155.55,P<0.0001)。
- 仅减csDMARD组复发风险较减bDMARD/tsDMARD组低91%(HR 0.09,95%CI 0.01-0.69,P=0.0213)。
核心结论
- 在病情控制良好的类风湿关节炎真实世界前瞻性RHEUMTAP队列中,减量或停用bDMARD/tsDMARD(无论是否联合背景治疗)的患者比未减任何药物及仅减csDMARD的患者更可能发生复发。
研究设计与样本
- 前瞻性队列研究,纳入持续缓解或低疾病活动度且稳定使用bDMARD/tsDMARD±csDMARD至少6个月的类风湿关节炎患者,接受减药/停药并随访2年。
- RHEUMTAP队列共131例符合入选标准,其中52例接受药物减量。
- 患者按减药情况分为四组评估复发:未减药组、仅减bDMARD/tsDMARD组、仅减csDMARD组、同时减csDMARD和bDMARD/tsDMARD组。
主要发现
- 减药组15例发生复发,未减药组2例发生复发。
- 任何减药/停药者较未减药者复发风险更高(HR 10.43,95%CI 2.98-36.53,P=0.0002)。
- 减bDMARD/tsDMARD组复发风险为未减药组的31倍(HR 31.43,95%CI 6.35-155.55,P<0.0001)。
- 同时减csDMARD和bDMARD/tsDMARD组复发风险为未减药组的18倍(HR 18.45,95%CI 2.55-133.37,P=0.0039)。
- 仅减csDMARD组复发风险较减bDMARD/tsDMARD组低91%(HR 0.09,95%CI 0.01-0.69,P=0.0213)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study had two aims: (i) to investigate outcomes of medication tapering in stable RA patients on biologic or targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) and conventional synthetic DMARDs (csDMARDs) in a real-world prospective cohort; and (ii) to evaluate possible predictors of flare with medication taper. METHODS: A prospective cohort of patients with RA in sustained remission or low disease activity while on stable bDMARD/tsDMARDs +/- csDMARDs for at least 6 months underwent medication tapering/stopping and was tracked for 2 years. Patients were evaluated for flares in four groups: no taper, only bDMARD/tsDMARD taper, only csDMARD taper and both csDMARD and bDMARD/tsDMARD taper. RESULTS: The RHEUMTAP cohort included 131 patients that met eligibility criteria, of which 52 patients underwent a medication taper. Flare was experienced by 15 patients in the taper and two in the no-taper groups. Patients undergoing any taper/stop overall were 10 times more likely to experience a flare compared with those not tapered (HR 10.43, 95% CI 2.98-36.53, P = 0.0002). The group tapering bDMARD/tsDMARD had 31 times higher risk of flare (HR 31.43, 95% CI 6.35-155.55, P <0.0001) than the no-taper group. Patients tapering both csDMARDs and bDMARD/tsDMARDs had 18 times higher risk of flare than the no-taper group (HR 18.45, 95% CI 2.55-133.37, P = 0.0039). The only csDMARD taper group had a 91% lower risk of flare than the bDMARD/tsDMARD taper group (HR 0.09, 95% CI 0.01-0.69, P = 0.0213). CONCLUSION: In our real-world prospective RHEUMTAP cohort study on the outcomes of different medication tapering groups in well-controlled RA, patients who tapered or stopped bDMARDs/tsDMARDs with or without background therapy were more likely to experience a flare than patients that did not taper any medications and those that tapered only csDMARDs.
引用
- Tageldin M, Wilson N, Yin Y, et al. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort. Rheumatology (Oxford). 2023. PMID: 37855679. doi:10.1093/rheumatology/kead430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。